Bioasis Technologies reports that it has granted stock options to acquire a total of 1,367,606 common shares effective June 30, 2020.
The company also announced the appointment of Dr. Jeffrey Sprouse PhD as Preclinical Program Manager. Dr. Sprouse brings over 20 years of drug discovery experience to his role at Bioasis.